Selumetinib was an inhibitor of mitogen-activated protein kinase 1 and 2 (MEK1/2), which were an upstream regulator of the ERK pathway and were frequently activated in a variety of cancers[45–47]. This evidence concerns the gene MAP4K1 and cancer.